AXA Investment Managers’s Vertex Pharmaceuticals VRTX Stock Holding History

AXA Investment Managers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$64.1M	Buy	+163,680	New	+$68.4M	0.17%	117

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AXA Investment Managers's VRTX Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2025: 163,680 shares worth $64.1M. The stake represents 0.17% of the portfolio and ranks #117 among its holdings.

1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

AXA Investment Managers held 163,680 shares of Vertex Pharmaceuticals worth $64.1M as of Q3 2025.
Vertex Pharmaceuticals was a new AXA Investment Managers position in Q3 2025.
Vertex Pharmaceuticals made up 0.17% of AXA Investment Managers's portfolio in Q3 2025, its #117 holding.
1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.